UMB Bank n.a. Has $20.91 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

UMB Bank n.a. lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 40,194 shares of the medical research company’s stock after selling 579 shares during the period. UMB Bank n.a.’s holdings in Thermo Fisher Scientific were worth $20,910,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in TMO. Intech Investment Management LLC grew its stake in Thermo Fisher Scientific by 19.4% in the second quarter. Intech Investment Management LLC now owns 3,142 shares of the medical research company’s stock valued at $1,738,000 after acquiring an additional 510 shares during the period. Pacer Advisors Inc. grew its stake in Thermo Fisher Scientific by 6.2% in the second quarter. Pacer Advisors Inc. now owns 28,900 shares of the medical research company’s stock valued at $15,982,000 after acquiring an additional 1,685 shares during the period. Thrivent Financial for Lutherans lifted its holdings in shares of Thermo Fisher Scientific by 5.5% in the second quarter. Thrivent Financial for Lutherans now owns 119,619 shares of the medical research company’s stock valued at $66,148,000 after purchasing an additional 6,185 shares in the last quarter. Summit Trail Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 3.9% in the second quarter. Summit Trail Advisors LLC now owns 4,164 shares of the medical research company’s stock valued at $2,304,000 after purchasing an additional 157 shares in the last quarter. Finally, Westwood Holdings Group Inc. lifted its holdings in shares of Thermo Fisher Scientific by 80.5% in the second quarter. Westwood Holdings Group Inc. now owns 2,226 shares of the medical research company’s stock valued at $1,231,000 after purchasing an additional 993 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the sale, the senior vice president now directly owns 12,736 shares in the company, valued at $7,134,197.76. This represents a 13.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the sale, the chief executive officer now owns 121,192 shares of the company’s stock, valued at $67,175,513.68. This represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 47,150 shares of company stock worth $25,954,465 in the last ninety days. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Trading Down 0.4 %

Shares of TMO stock opened at $559.72 on Monday. The business has a 50-day moving average price of $529.96 and a two-hundred day moving average price of $568.33. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The firm has a market cap of $214.09 billion, a P/E ratio of 35.09, a price-to-earnings-growth ratio of 3.59 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm had revenue of $10.60 billion during the quarter, compared to analysts’ expectations of $10.63 billion. During the same period in the prior year, the business earned $5.69 EPS. The company’s revenue for the quarter was up .2% compared to the same quarter last year. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its board has authorized a stock repurchase program on Friday, November 15th that allows the company to repurchase $4.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 2% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th were issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific’s payout ratio is currently 9.78%.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of recent research reports. Bernstein Bank raised their target price on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a report on Tuesday, October 22nd. Barclays dropped their target price on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Redburn Atlantic started coverage on Thermo Fisher Scientific in a report on Monday, October 14th. They set a “buy” rating and a $680.00 price target on the stock. Scotiabank initiated coverage on Thermo Fisher Scientific in a report on Monday, December 23rd. They set a “sector perform” rating and a $605.00 price target on the stock. Finally, Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. Four analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $648.95.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.